Evaluating YL202 for advanced breast cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label phase 2 clinical study aims to assess the efficacy, safety, and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer, specifically targeting those with triple-negative breast cancer (TNBC), hormone receptor-positive, and low or zero HER2 expression. Participants will receive intravenous infusions of YL202, and the study will measure treatment outcomes based on established criteria. The trial focuses on patients who have previously failed other treatments and are not candidates for curative surgery or radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Have been informed of the study before the start of the study and voluntarily sign name and date on the informed consent form.
2. Patients with locally advanced or metastatic disease (according to the UICC and AJCC staging system \[Version 8\]) who are not candidates for curative surgery or radiotherapy.
3. Patients who are pathologically confirmed advanced/unresectable or metastatic breast cancer with HR-negative and HER2-negative,.
4. Patients who are confirmed HR positive and HER2-Zero-expression and HER2-Low-expression.
5. Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC.
6. Have at least 1 extracranial measurable lesion as a target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
7. Have Adequate organ and bone marrow function within 7 days prior to the first dose.
8. Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
9. Have a expected survival ≥ 3 months.
10. Have ability and willingness to comply with protocol-specified visits and procedures.

Exclusion Criteria:

1. Have prior treatment with an agent targeting HER3.
2. Have prior intolerance to treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor.
3. Have been enrolled in another clinical study concurrently unless it is an observational clinical study or in the follow-up phase of an interventional study.
4. Have insufficient washout period for prior anticancer therapy prior to first dose of the study drug.
5. Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
6. Have prior allogeneic bone marrow transplant or prior solid organ transplant.
7. Have received treatment with systemic steroids.
8. Have received any live vaccine within 4 weeks prior to the first dose of study drug or intend to receive a live vaccine during the study.
9. Leptomeningeal metastases or carcinomatous meningitis, spinal cord compression.
10. Brain metastases with the exceptions.
11. Have uncontrolled or clinically significant cardiovascular and cerebrovascular disease.
12. Have clinically significant concomitant pulmonary diseases.
13. Have a diagnosis of Gilbert's syndrome.
14. Have pleural effusion, abdominal effusion.
15. Have a history of gastrointestinal perforation and or fistula within 6 months prior to the first dose.
16. Have serious infection.
17. Patients with human immunodeficiency virus (HIV) infection.
18. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
19. Have any other primary malignancy within 5 years prior to the first dose of study drug.
20. Have unresolved toxicities from prior anticancer therapy.
21. Have a history of severe hypersensitivity reactions to the drug substance, inactive ingredients in the drug product, or other monoclonal antibodies.
22. Lactating women, or women who are confirmed to be pregnant by pregnancy test within 3 days prior to the first dose.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: MediLink Study Team
• Email: clinicaltrials@medilinkthera.com
• Phone: +86 512 62858368

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can compression or ice gloves and socks reduce neuropathy from UTD1 in advanced breast cancer

  This randomized phase III trial tests whether compression gloves/socks or ice gloves/socks can reduce nerve problems in women with advanced breast cancer undergoing UTD1 treatment.

  Recruiting Fudan University · Shanghai · NCT07638774

• YL202 vs physician's choice in HR+/HER2- breast cancer

  This trial tests YL202 against a physician's choice of approved drugs in people with HR+/HER2- breast cancer that has spread or cannot be surgically removed and who have had at least one prior chemotherapy.

  Recruiting Phase 3 MediLink Therapeutics (Suzhou) Co., Ltd. · Shanghai, Shanghai Municipality · NCT07461454

• HRS-8080 plus dalpiciclib versus fulvestrant plus dalpiciclib for advanced or metastatic breast cancer after adjuvant endocrine therapy resistance

  This trial tests whether adding the new drug HRS-8080 to dalpiciclib works better than fulvestrant with dalpiciclib for people with advanced or metastatic breast cancer that became resistant to prior adjuvant hormonal therapy.

  Recruiting Phase 3 Shandong Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07354022

• Using SPH4336 with hormone therapy for advanced breast cancer

  This study is testing a new treatment called SPH4336 combined with hormone therapy to see if it helps people with advanced breast cancer that hasn't responded to other treatments.

  Recruiting at 22 sites Phase 2/3 Shanghai Pharmaceuticals Holding Co., Ltd · Guangzhou, Guangdong and 21 other locations · NCT05860465

• New treatment for advanced breast cancer using SPH4336 and letrozole

  This study is testing if a new treatment combining SPH4336 with letrozole can help women with advanced breast cancer feel better compared to just taking letrozole with a placebo.

  Recruiting at 9 sites Phase 2/3 Shanghai Pharmaceuticals Holding Co., Ltd · Fuzhou, Fujian and 8 other locations · NCT05744687

• Comparing utidelone and docetaxel for advanced breast cancer

  This study is testing whether a new drug called utidelone works better than docetaxel for women with advanced breast cancer that is HER2-negative.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Gangdong and 1 other locations · NCT05430399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.